After raising $9 million, a Rochester biotechnology firm is building a state-of-the-art headquarters to manufacture anti-cancer vaccines on the former IBM campus.
Vyriad announced this morning that it had raised the money needed to build a “Good Manufacturing Practice” facility to produce the company’s clinical-stage oncolytic virus therapies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,